ClinicalTrials.gg
TerminatedNCT00494338Updated Oct 1, 2009

Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer

A Phase 2 interventional study of Docetaxel in Metastatic Prostate Cancer, sponsored by Sanofi. Terminated at 1 site in Brazil. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-10-01.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Why this study was terminated
due to celecoxib safety issues

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 193 studies testing docetaxel in Prostatic Neoplasms — 15 open to participants now, 24 under way, 10 of them phase 3. Docetaxel · Prostatic Neoplasms.

Enrollment
164th of 185
6 · median 39
Started
2004
with 18 others
Phase 2
104 of 193
4 open now
Registered
90th of 193
by date
Lead sponsor
11 of 193
Sanofi

Among the 193 studies testing docetaxel in Prostatic Neoplasms, this one is the 164th largest by enrollment of the 185 interventional ones that give a count, is one of 19 that started in 2004, is one of 104 in phase 2, and was the 90th registered.

Prostatic Neoplasms

7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 193 studies testing docetaxel in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies testing docetaxel in Prostatic Neoplasms, or all of them as a file.
02

Study summary

A multi-center controlled, non-comparative open Phase II trial of docetaxel and celecoxib in patients with metastatic androgen independent prostate cancer where efficacy is measured by PSA response defined as a 50% reduction in PSA maintained on two consecutive evaluations at least 4 weeks apart.

03

Conditions studied

  • Metastatic Prostate Cancer

Browse trials for

Keywords

  • Metastatic Androgen Independent Prostate Cancer (MAIPC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with confirmed MAIPC
  • Documented progressive disease in bone, soft tissue or PSA despite castrate levels of testosterone
  • If LHRH agonist were used previously it must be kept
  • Previous anti-androgen should be held at least 4 weeks for flutamida or cyproterone and 6 weeks for bycalumida
  • Previous DES should be held for at least 4 weeks before partcipating in the trial
  • Chemotherapy naive patients
  • No prior radioisotope
  • Less than 25% of bone marrow should be irradiated for prior palliative radiotherapy
  • > 70%
  • Adequate hematologic, hepatic and renal function

Exclusion criteria

Exclusion Criteria:

  • Patients with serious medical illness
  • History of significant active cardiac disease
  • History of gastrointestinal ulceration, bleeding or perforation
  • History of myocardial infarctin within past 12 months
  • Allergy to sulfonamides or to celecoxib or history of urticaria to any NSAID

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy of docetaxel and celecoxib by PSA response defined as a 50% reduction in PSA maintained on two consecutive evaluations at least 4 weeks apart

    Time frame: two consecutive evaluations at least 4 weeks apart

Secondary outcomes

  1. Response in measurable disease by response evaluation criteria in solid tumors (RECIST) criteria, time to progression, overall survival and toxicity by Natonal Cancer Institute Commum Toxicity Criteria version 2.0.

    Time frame: response evaluation criteria in solid tumors (RECIST) criteria, time to progression, overall survival and toxicity by Natonal Cancer Institute Commum Toxicity Criteria version 2.0.

07

Study locations

1 site
  • Sanofi-Aventis
    Sao Paulo, Brazil
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2004, a primary completion of Apr 2005 and a completion of Apr 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2007
First posted
Jun 29, 2007
Start
Nov 2004
Primary completionActual
Apr 2005
CompletionActual
Apr 2005
Last update
Oct 1, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00494338
Lead sponsor
Sanofi
First posted
Jun 29, 2007
Start date
Nov 2004
Primary completion
Apr 2005
Completion
Apr 2005
Last update
Oct 1, 2009

Study contacts

Jaderson Lima, M.D.
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Docetaxel

Start the discussion